Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy

INTRODUCTION: The fixed-ratio combinations (FRCs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and basal insulin, insulin glargine 100 U/mL plus lixisenatide (iGlarLixi), and insulin degludec plus liraglutide (iDegLira), have demonstrated safety and efficacy in patients with type 2 diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrimmon, Rory J., Lamotte, Mark, Ramos, Mafalda, Alsaleh, Abdul Jabbar Omar, Souhami, Elisabeth, Lew, Elisheva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586382/
https://www.ncbi.nlm.nih.gov/pubmed/34714524
http://dx.doi.org/10.1007/s13300-021-01156-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586382/
https://www.ncbi.nlm.nih.gov/pubmed/34714524
http://dx.doi.org/10.1007/s13300-021-01156-1

Ejemplares similares